Zymeworks Inc. — Director's Dealing 2024

Jan 9, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Zymeworks Inc. (ZYME)
CIK: 0001937653
Period of Report: 2024-01-05

Reporting Person: Astle Christopher (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-01-05	Common Stock	M	10500	$0.00	Acquired	12497	Direct
2024-01-05	Common Stock	S	4563	$10.6522	Disposed	7934	Direct
2024-01-08	Common Stock	S	1431	$11.2156	Disposed	6503	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-01-05	Restricted Stock Unit	$	M	10500	Disposed		Common Stock (10500)	Direct
2024-01-05	Stock Option (Right to Buy)	$10.56	A	50000	Acquired	2034-01-04	Common Stock (50000)	Direct
2024-01-05	Restricted Stock Unit	$	A	30000	Acquired		Common Stock (30000)	Direct

Footnotes

F1: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 5, 2023.

F2: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.55 to $10.845, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.49 to $11.58, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F5: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.

F6: The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on January 5, 2024.

F7: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.

F8: The RSUs vest in three equal annual installments beginning on January 5, 2025.